Cargando…

Cidofovir in the treatment of poxvirus infections

Cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, HPMPC] has since 1996 been licensed for clinical use in the treatment of cytomegalovirus (CMV) retinitis in AIDS patients. Cidofovir has broad-spectrum activity against virtually all DNA viruses, including herpes-, adeno-, polyoma-, pap...

Descripción completa

Detalles Bibliográficos
Autor principal: De Clercq, Erik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science B.V. 2002
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9533828/
https://www.ncbi.nlm.nih.gov/pubmed/12076747
http://dx.doi.org/10.1016/S0166-3542(02)00008-6
_version_ 1784802425925795840
author De Clercq, Erik
author_facet De Clercq, Erik
author_sort De Clercq, Erik
collection PubMed
description Cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, HPMPC] has since 1996 been licensed for clinical use in the treatment of cytomegalovirus (CMV) retinitis in AIDS patients. Cidofovir has broad-spectrum activity against virtually all DNA viruses, including herpes-, adeno-, polyoma-, papilloma- and poxviruses. Among the poxviruses, vaccinia, variola (smallpox), cowpox, monkeypox, camelpox, molluscum contagiosum and orf have proven sensitive to the inhibitory effects of cidofovir. In vivo, cidofovir has shown high efficacy, even after administration of a single systemic (intraperitoneal) or intranasal (aerosolized) dose, in protecting mice from a lethal respiratory infection with either vaccinia or cowpox. Cidofovir has also demonstrated high effectiveness in the treatment of vaccinia virus infection in severe combined immune deficiency mice. In humans, cidofovir has been used successfully in the treatment, by both the topical and intravenous route, of recalcitrant molluscum contagiosum and orf in immunocompromised patients. Taken together, these data indicate that cidofovir should be effective in the therapy and short-term prophylaxis of smallpox and related poxvirus infections in humans, as well as the treatment of the complications of vaccinia that may arise in immunocompromised patients inadvertently inoculated with the smallpox vaccine (vaccinia).
format Online
Article
Text
id pubmed-9533828
institution National Center for Biotechnology Information
language English
publishDate 2002
publisher Elsevier Science B.V.
record_format MEDLINE/PubMed
spelling pubmed-95338282022-10-07 Cidofovir in the treatment of poxvirus infections De Clercq, Erik Antiviral Res Review Cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, HPMPC] has since 1996 been licensed for clinical use in the treatment of cytomegalovirus (CMV) retinitis in AIDS patients. Cidofovir has broad-spectrum activity against virtually all DNA viruses, including herpes-, adeno-, polyoma-, papilloma- and poxviruses. Among the poxviruses, vaccinia, variola (smallpox), cowpox, monkeypox, camelpox, molluscum contagiosum and orf have proven sensitive to the inhibitory effects of cidofovir. In vivo, cidofovir has shown high efficacy, even after administration of a single systemic (intraperitoneal) or intranasal (aerosolized) dose, in protecting mice from a lethal respiratory infection with either vaccinia or cowpox. Cidofovir has also demonstrated high effectiveness in the treatment of vaccinia virus infection in severe combined immune deficiency mice. In humans, cidofovir has been used successfully in the treatment, by both the topical and intravenous route, of recalcitrant molluscum contagiosum and orf in immunocompromised patients. Taken together, these data indicate that cidofovir should be effective in the therapy and short-term prophylaxis of smallpox and related poxvirus infections in humans, as well as the treatment of the complications of vaccinia that may arise in immunocompromised patients inadvertently inoculated with the smallpox vaccine (vaccinia). Elsevier Science B.V. 2002-07 2002-02-16 /pmc/articles/PMC9533828/ /pubmed/12076747 http://dx.doi.org/10.1016/S0166-3542(02)00008-6 Text en Copyright © 2002 Elsevier Science B.V. All rights reserved. Elsevier has created a Monkeypox Information Center (https://www.elsevier.com/connect/monkeypox-information-center) in response to the declared public health emergency of international concern, with free information in English on the monkeypox virus. The Monkeypox Information Center is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its monkeypox related research that is available on the Monkeypox Information Center - including this research content - immediately available in publicly funded repositories, with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the Monkeypox Information Center remains active.
spellingShingle Review
De Clercq, Erik
Cidofovir in the treatment of poxvirus infections
title Cidofovir in the treatment of poxvirus infections
title_full Cidofovir in the treatment of poxvirus infections
title_fullStr Cidofovir in the treatment of poxvirus infections
title_full_unstemmed Cidofovir in the treatment of poxvirus infections
title_short Cidofovir in the treatment of poxvirus infections
title_sort cidofovir in the treatment of poxvirus infections
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9533828/
https://www.ncbi.nlm.nih.gov/pubmed/12076747
http://dx.doi.org/10.1016/S0166-3542(02)00008-6
work_keys_str_mv AT declercqerik cidofovirinthetreatmentofpoxvirusinfections